ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA)

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2016–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	4	1
2023	—	4	1
2022	—	4	1
2021	—	4	1
2020	—	4	1
2019	—	4	1
2018	—	4	1
2017	—	4	1
2016	—	5	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
FIERCE GOVERNMENT RELATIONS	—	44

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	43
HOUSE OF REPRESENTATIVES	38
Executive Office of the President (EOP)	8
Health & Human Services, Dept of (HHS)	5
Centers For Medicare and Medicaid Services (CMS)	2
Food & Drug Administration (FDA)	2
Treasury, Dept of	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Pharmacy	Pharmacy	44
Trade (domestic/foreign)	Trade (domestic/foreign)	3
Medicare/Medicaid	Medicare/Medicaid	3
Copyright/Patent/Trademark	Copyright/Patent/Trademark	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

S. 1414119th Congress

Expedited Access to Biosimilars Act

2026 · third_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Biosimilars; Generic drugs; Issues around country of origin labeling; Supply Chain; S.2658 - Medication Affordability and Patent Integrity Act; S.3014 - Ensuring Timely Access to Generics Act; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act; S.43 - Skinny Labels, Big Savings Act; Tariffs; General Business Issues.

Client expense: — · Firm income: $60,000

Matched citations: S.1414

S. 1954119th Congress

Biosimilar Red Tape Elimination Act

2026 · third_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Biosimilars; Generic drugs; Issues around country of origin labeling; Supply Chain; S.2658 - Medication Affordability and Patent Integrity Act; S.3014 - Ensuring Timely Access to Generics Act; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act; S.43 - Skinny Labels, Big Savings Act; Tariffs; General Business Issues.

Client expense: — · Firm income: $60,000

Matched citations: S.1954

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · third_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Biosimilars; Generic drugs; Issues around country of origin labeling; Supply Chain; S.2658 - Medication Affordability and Patent Integrity Act; S.3014 - Ensuring Timely Access to Generics Act; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act; S.43 - Skinny Labels, Big Savings Act; Tariffs; General Business Issues.

Client expense: — · Firm income: $60,000

Matched citations: S.2658

S. 3014119th Congress

Ensuring Timely Access to Generics Act of 2025

2026 · third_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Biosimilars; Generic drugs; Issues around country of origin labeling; Supply Chain; S.2658 - Medication Affordability and Patent Integrity Act; S.3014 - Ensuring Timely Access to Generics Act; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act; S.43 - Skinny Labels, Big Savings Act; Tariffs; General Business Issues.

Client expense: — · Firm income: $60,000

Matched citations: S.3014

Show 21 more cited filings

S. 3788119th Congress

CLEAR LABELS Act

2026 · third_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Biosimilars; Generic drugs; Issues around country of origin labeling; Supply Chain; S.2658 - Medication Affordability and Patent Integrity Act; S.3014 - Ensuring Timely Access to Generics Act; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act; S.43 - Skinny Labels, Big Savings Act; Tariffs; General Business Issues.

Client expense: — · Firm income: $60,000

Matched citations: S.3788

S. 43119th Congress

Skinny Labels, Big Savings Act

2026 · third_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Biosimilars; Generic drugs; Issues around country of origin labeling; Supply Chain; S.2658 - Medication Affordability and Patent Integrity Act; S.3014 - Ensuring Timely Access to Generics Act; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act; S.43 - Skinny Labels, Big Savings Act; Tariffs; General Business Issues.

Client expense: — · Firm income: $60,000

Matched citations: S.43

H.R. 7410117th Congress

American Made Medicine Act

2026 · second_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

H.R.7410 - American Made Medicine Act; Drug shortages; Generic drugs; Issues around country of origin labeling; S.4327 - Securing America's Drug Supply from Communist China Act; S.2658 - Medication Affordability and Patent Integrity Act; S.3014 - Ensuring Timely Access to Generics Act; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act; S.4784 - Fiscal Year 2027 National Defense Authorization Act; Supply chain.

Client expense: — · Firm income: $60,000

Matched citations: H.R.7410

S. 1414119th Congress

Expedited Access to Biosimilars Act

2026 · second_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

H.R.7410 - American Made Medicine Act; Drug shortages; Generic drugs; Issues around country of origin labeling; S.4327 - Securing America's Drug Supply from Communist China Act; S.2658 - Medication Affordability and Patent Integrity Act; S.3014 - Ensuring Timely Access to Generics Act; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act; S.4784 - Fiscal Year 2027 National Defense Authorization Act; Supply chain.

Client expense: — · Firm income: $60,000

Matched citations: S.1414

S. 1954119th Congress

Biosimilar Red Tape Elimination Act

2026 · second_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

H.R.7410 - American Made Medicine Act; Drug shortages; Generic drugs; Issues around country of origin labeling; S.4327 - Securing America's Drug Supply from Communist China Act; S.2658 - Medication Affordability and Patent Integrity Act; S.3014 - Ensuring Timely Access to Generics Act; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act; S.4784 - Fiscal Year 2027 National Defense Authorization Act; Supply chain.

Client expense: — · Firm income: $60,000

Matched citations: S.1954

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · second_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

H.R.7410 - American Made Medicine Act; Drug shortages; Generic drugs; Issues around country of origin labeling; S.4327 - Securing America's Drug Supply from Communist China Act; S.2658 - Medication Affordability and Patent Integrity Act; S.3014 - Ensuring Timely Access to Generics Act; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act; S.4784 - Fiscal Year 2027 National Defense Authorization Act; Supply chain.

Client expense: — · Firm income: $60,000

Matched citations: S.2658

S. 3014119th Congress

Ensuring Timely Access to Generics Act of 2025

2026 · second_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

H.R.7410 - American Made Medicine Act; Drug shortages; Generic drugs; Issues around country of origin labeling; S.4327 - Securing America's Drug Supply from Communist China Act; S.2658 - Medication Affordability and Patent Integrity Act; S.3014 - Ensuring Timely Access to Generics Act; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act; S.4784 - Fiscal Year 2027 National Defense Authorization Act; Supply chain.

Client expense: — · Firm income: $60,000

Matched citations: S.3014

S. 3788119th Congress

CLEAR LABELS Act

2026 · second_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

H.R.7410 - American Made Medicine Act; Drug shortages; Generic drugs; Issues around country of origin labeling; S.4327 - Securing America's Drug Supply from Communist China Act; S.2658 - Medication Affordability and Patent Integrity Act; S.3014 - Ensuring Timely Access to Generics Act; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act; S.4784 - Fiscal Year 2027 National Defense Authorization Act; Supply chain.

Client expense: — · Firm income: $60,000

Matched citations: S.3788

S. 4327119th Congress

Securing America’s Drug Supply from Communist China Act

2026 · second_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

H.R.7410 - American Made Medicine Act; Drug shortages; Generic drugs; Issues around country of origin labeling; S.4327 - Securing America's Drug Supply from Communist China Act; S.2658 - Medication Affordability and Patent Integrity Act; S.3014 - Ensuring Timely Access to Generics Act; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act; S.4784 - Fiscal Year 2027 National Defense Authorization Act; Supply chain.

Client expense: — · Firm income: $60,000

Matched citations: S.4327

S. 4784119th Congress

National Defense Authorization Act for Fiscal Year 2027

2026 · second_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

H.R.7410 - American Made Medicine Act; Drug shortages; Generic drugs; Issues around country of origin labeling; S.4327 - Securing America's Drug Supply from Communist China Act; S.2658 - Medication Affordability and Patent Integrity Act; S.3014 - Ensuring Timely Access to Generics Act; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act; S.4784 - Fiscal Year 2027 National Defense Authorization Act; Supply chain.

Client expense: — · Firm income: $60,000

Matched citations: S.4784

S. 1414119th Congress

Expedited Access to Biosimilars Act

2026 · first_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Supply Chain; Drug Shortages; Generic Drugs; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act;S.3510 - Biosimilar Inspection Modernization Act; API; Issues around Country of Origin labeling.

Client expense: — · Firm income: $60,000

Matched citations: S.1414

S. 1954119th Congress

Biosimilar Red Tape Elimination Act

2026 · first_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Supply Chain; Drug Shortages; Generic Drugs; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act;S.3510 - Biosimilar Inspection Modernization Act; API; Issues around Country of Origin labeling.

Client expense: — · Firm income: $60,000

Matched citations: S.1954

S. 3510119th Congress

Biosimilar Inspection Modernization Act of 2025

2026 · first_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Supply Chain; Drug Shortages; Generic Drugs; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act;S.3510 - Biosimilar Inspection Modernization Act; API; Issues around Country of Origin labeling.

Client expense: — · Firm income: $60,000

Matched citations: S.3510

S. 3788119th Congress

CLEAR LABELS Act

2026 · first_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Supply Chain; Drug Shortages; Generic Drugs; S.1414 - Expedited Access to Biosimilars Act; S.1954 - Biosimilar Red Tape Reduction Act; S.3788 - Clear Labels Act;S.3510 - Biosimilar Inspection Modernization Act; API; Issues around Country of Origin labeling.

Client expense: — · Firm income: $60,000

Matched citations: S.3788

H.R. 1262119th Congress

Mikaela Naylon Give Kids a Chance Act

2025 · fourth_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Supply Chain, Drug Shortages, Tariffs, Patent Thickets, Patent Settlements, Generic Drugs, S.43 - Skinny Labels, Big Savings Act, S.1041 - Affordable Prescriptions for Patients Act, S.1096 - Preserve Access to Affordable Generics and Biosimilars Act, S.1302 - A Bill to Provide for Increased Transparency in Generic Drug Applications, S.1414 - Expedited Access to Biosimilars Act, S.1954 - Biosimilar Red Tape Reduction Act, S.2296 - National Defense Authorization Act for FY 2026, H.R.1262 - Give Kids a Chance Act, H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026

Client expense: — · Firm income: $60,000

Matched citations: H.R.1262

H.R. 3838119th Congress

Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026

2025 · fourth_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Supply Chain, Drug Shortages, Tariffs, Patent Thickets, Patent Settlements, Generic Drugs, S.43 - Skinny Labels, Big Savings Act, S.1041 - Affordable Prescriptions for Patients Act, S.1096 - Preserve Access to Affordable Generics and Biosimilars Act, S.1302 - A Bill to Provide for Increased Transparency in Generic Drug Applications, S.1414 - Expedited Access to Biosimilars Act, S.1954 - Biosimilar Red Tape Reduction Act, S.2296 - National Defense Authorization Act for FY 2026, H.R.1262 - Give Kids a Chance Act, H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026

Client expense: — · Firm income: $60,000

Matched citations: H.R.3838

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2025 · fourth_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Supply Chain, Drug Shortages, Tariffs, Patent Thickets, Patent Settlements, Generic Drugs, S.43 - Skinny Labels, Big Savings Act, S.1041 - Affordable Prescriptions for Patients Act, S.1096 - Preserve Access to Affordable Generics and Biosimilars Act, S.1302 - A Bill to Provide for Increased Transparency in Generic Drug Applications, S.1414 - Expedited Access to Biosimilars Act, S.1954 - Biosimilar Red Tape Reduction Act, S.2296 - National Defense Authorization Act for FY 2026, H.R.1262 - Give Kids a Chance Act, H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026

Client expense: — · Firm income: $60,000

Matched citations: S.1041

S. 1096119th Congress

Preserve Access to Affordable Generics and Biosimilars Act

2025 · fourth_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Supply Chain, Drug Shortages, Tariffs, Patent Thickets, Patent Settlements, Generic Drugs, S.43 - Skinny Labels, Big Savings Act, S.1041 - Affordable Prescriptions for Patients Act, S.1096 - Preserve Access to Affordable Generics and Biosimilars Act, S.1302 - A Bill to Provide for Increased Transparency in Generic Drug Applications, S.1414 - Expedited Access to Biosimilars Act, S.1954 - Biosimilar Red Tape Reduction Act, S.2296 - National Defense Authorization Act for FY 2026, H.R.1262 - Give Kids a Chance Act, H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026

Client expense: — · Firm income: $60,000

Matched citations: S.1096

S. 1302119th Congress

Increasing Transparency in Generic Drug Applications Act

2025 · fourth_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Supply Chain, Drug Shortages, Tariffs, Patent Thickets, Patent Settlements, Generic Drugs, S.43 - Skinny Labels, Big Savings Act, S.1041 - Affordable Prescriptions for Patients Act, S.1096 - Preserve Access to Affordable Generics and Biosimilars Act, S.1302 - A Bill to Provide for Increased Transparency in Generic Drug Applications, S.1414 - Expedited Access to Biosimilars Act, S.1954 - Biosimilar Red Tape Reduction Act, S.2296 - National Defense Authorization Act for FY 2026, H.R.1262 - Give Kids a Chance Act, H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026

Client expense: — · Firm income: $60,000

Matched citations: S.1302

S. 1414119th Congress

Expedited Access to Biosimilars Act

2025 · fourth_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Supply Chain, Drug Shortages, Tariffs, Patent Thickets, Patent Settlements, Generic Drugs, S.43 - Skinny Labels, Big Savings Act, S.1041 - Affordable Prescriptions for Patients Act, S.1096 - Preserve Access to Affordable Generics and Biosimilars Act, S.1302 - A Bill to Provide for Increased Transparency in Generic Drug Applications, S.1414 - Expedited Access to Biosimilars Act, S.1954 - Biosimilar Red Tape Reduction Act, S.2296 - National Defense Authorization Act for FY 2026, H.R.1262 - Give Kids a Chance Act, H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026

Client expense: — · Firm income: $60,000

Matched citations: S.1414

S. 1954119th Congress

Biosimilar Red Tape Elimination Act

2025 · fourth_quarter · Firm: FIERCE GOVERNMENT RELATIONS

Open original LDA filing ↗

Cited source text and reported amounts

Supply Chain, Drug Shortages, Tariffs, Patent Thickets, Patent Settlements, Generic Drugs, S.43 - Skinny Labels, Big Savings Act, S.1041 - Affordable Prescriptions for Patients Act, S.1096 - Preserve Access to Affordable Generics and Biosimilars Act, S.1302 - A Bill to Provide for Increased Transparency in Generic Drug Applications, S.1414 - Expedited Access to Biosimilars Act, S.1954 - Biosimilar Red Tape Reduction Act, S.2296 - National Defense Authorization Act for FY 2026, H.R.1262 - Give Kids a Chance Act, H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026

Client expense: — · Firm income: $60,000

Matched citations: S.1954

Source: Senate LDA

ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA) — Lobbying Disclosure | Poliscope